Offset Mechanisms in Evaluation of Lumbar Medial Branch Blocks
Launched by UNIVERSITY OF PITTSBURGH · Jul 23, 2023
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how certain pain relief techniques, specifically lumbar medial branch blocks (MBB), affect pain management for people with chronic lower back pain. The trial aims to understand how the body’s central nervous system (the part of the body that controls pain signals) helps reduce pain after receiving this treatment.
To be eligible for the study, participants should be at least 18 years old and scheduled for an MBB at UPMC Pain Management clinics. They should be experiencing daily lower back pain for at least three months, with a pain level of 3 or higher on a scale of 0 to 10. Participants will need to be able to communicate in English and complete some questionnaires. While in the trial, participants can expect to receive regular phone calls related to the study. The trial is currently recruiting participants, and it's important for anyone interested to discuss their eligibility with their healthcare provider.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Scheduled for lumbar MBB in UPMC Pain Management clinics
- • Age \> 18 years old
- • Predominantly axial chronic low back pain at least 3 months on a daily basis
- • Must meet the minimum criteria for cognitive function using the PROMIS 2-item cognitive screener (\>3)
- • Low back pain intensity of \> 3/10
- • Willing and able to receive study-related phone calls
- Exclusion Criteria:
- • History of spine surgery at the level of the lumbar MBB
- • Active worker's compensation or litigation claims
- • New pain and/or psychiatric treatments within 2 weeks of enrollment
- • Not fluent in English and/or not able to complete the questionnaires
- • Any clinically unstable systemic illness that is judged to interfere with the study
About University Of Pittsburgh
The University of Pittsburgh is a leading research institution known for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a robust infrastructure for research and a multidisciplinary approach, the university fosters collaboration among experts in various fields, facilitating the development of novel therapies and interventions. Its clinical trial programs emphasize ethical standards, patient safety, and the integration of cutting-edge technology, making the University of Pittsburgh a pivotal contributor to the landscape of clinical research and a trusted partner in the pursuit of health advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Patients applied
Trial Officials
Benedict J Alter, MD, PhD
Principal Investigator
University of Pittsburgh
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported